TABLE 1.
Characteristics of the Study Subjects
| Characteristic | n* | Description† |
|---|---|---|
| Age at HAART (yrs) | 1084 | 34.2 (7.6) |
| Female gender | 1085 | 68 (6.3%) |
| Ethnicity | ||
| European Americans | 1085 | 488 (45.0%) |
| African Americans | 476 (43.9%) | |
| Hispanic Americans | 84 (7.7%) | |
| Others | 37 (3.4%) | |
| CD4+ T cell counts (cells/μL) | ||
| Baseline‡ | 1085 | 470 (338–630) |
| Nadir‡ | 1085 | 311 (225–414) |
| Mean of phase II‡ | 1085 | 577 (422–741) |
| VL parameters | ||
| Baseline VL (log10 copies/mL) | 1082 | 4.28 (0.83) |
| Pre HAART VL (log10 copies/mL) | 1045 | 4.23 (0.75) |
| Cumulative VL (log10 copy-months/mL) | 1081 | 18.85 (10.4) |
| Overall VL decay constant | 1085 | 0.026 (0.086) |
| Temporal characteristics | ||
| Seroconversion window (yrs)‡ | 1085 | 1.37 (0.87–2.42) |
| HIV diagnosis to first CD4 (days) ‡ | 1085 | 39 (26–63) |
| HIV diagnosis to HAART (yrs) ‡ | 1085 | 2.34 (0.27–5.71) |
| Nadir to HAART (mo)‡ | 1085 | 2.00 (0.26–12.78) |
| Follow-up on HAART (yrs)‡ | 1085 | 7.58 (4.41–10.15) |
| HAART to VL suppression (yrs)‡ | 1075 | 0.41 (0.13–1.03) |
| Other characteristics | ||
| Initiated in late HAART era | 1085 | 750 (69.1%) |
| AIDS before HAART initiation | 1085 | 29 (2.7%) |
| Prior use of ART | 1085 | 519 (7.8%) |
*
Number of subjects on whom indicated data was available.
†
For continuous variables, the values represent mean (SD).
‡
For continuous variables not following normal distribution, the values represent median (interquartile range width).
§
Interval between the last HIV-negative test to the first HIV-positive test.